These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy]. Qi SY; Wang M; Xu Y Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266 [TBL] [Abstract][Full Text] [Related]
9. Current immunotherapeutic strategies in prostate cancer. Grosso JF; Drake CG Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549 [TBL] [Abstract][Full Text] [Related]
10. Current vaccination strategies for prostate cancer. Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436 [TBL] [Abstract][Full Text] [Related]
11. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. Minev BR; Guo F; Gueorguieva I; Kaiser HE In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883 [TBL] [Abstract][Full Text] [Related]
12. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Arlen PM; Gulley JL; Tsang KY; Schlom J Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334 [TBL] [Abstract][Full Text] [Related]
13. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccines for the treatment of prostate cancer. Lehrfeld TJ; Lee DI Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314 [TBL] [Abstract][Full Text] [Related]
15. Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory? Slovin SF Expert Rev Anticancer Ther; 2008 Mar; 8(3):465-74. PubMed ID: 18366293 [TBL] [Abstract][Full Text] [Related]